MediWound Ltd.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $169.6M
- Price
- $13.21
- % Change (Daily % change from the live per-ticker quote feed.)
- +0.72%
- Volume
- 79.8K
About
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
Quick stats
Shares outstanding12.8M
Computed float9.6M
Float / shares75.0%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001593984
Websitehttps://www.mediwound.com
AI Summary
AI-generated1/12
minormixedearnings
MediWound Reports Second Quarter 2026 Financial Results and Provides Corporate Update
MediWound reported Q2 revenue of $3.1 million, down from $5.7 million in the prior year, with a net loss of $7.4 million and a cash position of $36 million following $20 million in cash burn during the first half.
The company reaffirmed its full-year 2026 revenue guidance of $24–26 million, driven by expected contributions from a new Master Services Agreement with Vericel under its BARDA contract.
Operational updates included record quarterly revenue and hospital unit sales for NexoBrid, while the Phase III VALUE trial for EscharEx remains on track for interim assessment and enrollment completion by the end of Q1 2027.
Red flags
- Revenue declined year-over-year from $5.7 million to $3.1 million
- Cash position dropped from $54 million to $36 million in the first half of 2026